



Supplemental Fig. 1 Wasiak et al.

a



b




Supplemental Fig. 2 Wasiak et al.


a

Complement gene (Treatment time)	IC50 (uM)	
	RVX-208	JQ1
MBL2 (48h)	16.3	0.16
C1S (48h)	18.9	0.30
C2 (48h)	>50	ND
C3 (48h)	1.90	0.20
C4a/4b (48h)	6.30	ND
C5 (48h)	>30	ND
C5 (72h)	21.8	0.27

b




Supplemental Fig. 3 Wasiak et al.




Supplemental Fig. 4 Wasiak et al.


a




b




Supplemental Fig. 5 Wasiak et al.



Supplemental Fig. 6 Wasiak et al.



Supplemental Fig. 7 Wasiak et al.



Supplemental Table 1 Wasiak et al.

Study	ASSERT 12-Week Study		ASSURE 26-Week Study		Total	
	RVX-208 (N=75)	Placebo (N=74)	RVX-208 (N=243)	Placebo (N=80)	RVX-208 (N=318)	Placebo (N=154)
Infections and Infestations	13 (17.3%)	16 (21.6%)	32 (13.2%)	10 (12.5%)	73 (15.6%)	26 (16.9%)